LY3372689 clinical trials
Also written LY3372689.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses LY3372689 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY3372689
- 5
Studies by the year they started
6 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses LY3372689 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseCompletedPhase 2Eli Lilly and CompanyNCT05063539Written as LY3372689
- A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05749848Written as [¹⁴C]-LY3372689
- A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04392271Written as LY3372689
- A Safety Study of LY3372689 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04106206Written as LY3372689
- A Study of the Effects of LY3372689 on the Brain in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03944031Written as LY3372689
- A Safety Study of LY3372689 Given By Mouth to Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03819270Written as LY3372689
Codes
What other systems call LY3372689 · ClinicalTrials.gg INT018065
- UNII (FDA) U0SGP6ZX2VCEPEROGNASTATConfirmed FDA, Wikidata
- Wikidata Q111357415LY3372689Confirmed FDA, Wikidata
- DrugBank DB21591One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U0SGP6ZX2V | CEPEROGNASTAT | Confirmed FDA, Wikidata |
| Wikidata | Q111357415 | LY3372689 | Confirmed FDA, Wikidata |
| DrugBank | DB21591 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.